R
Ranjani Manjunath
Researcher at GlaxoSmithKline
Publications - 5
Citations - 399
Ranjani Manjunath is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Epilepsy & Dopaminergic. The author has an hindex of 5, co-authored 5 publications receiving 357 citations.
Papers
More filters
Journal ArticleDOI
Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians
Collin A. Hovinga,Miya R. Asato,Ranjani Manjunath,James W. Wheless,Stephanie J. Phelps,Raj D. Sheth,Jesus E. Pina-Garza,Wendy M. Zingaro,Lisa S. Haskins +8 more
TL;DR: Patient-oriented epilepsy treatment programs and clear communication strategies to promote self-management and patients' understanding of epilepsy are essential to maximizing treatment and quality of life outcomes while also minimizing economic costs.
Journal ArticleDOI
Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample
Richard P. Allen,William G. Ondo,Eric Ball,Michael Calloway,Ranjani Manjunath,Rachel L. Higbie,Mechele R. Lee,Paul A. Nisbet +7 more
TL;DR: It is important for physicians to carefully screen patients for changes in RLS Symptoms for as long as they are on dopamine agents, with particular attention paid to those patients who present with the most severe RLS symptoms prior to treatment initiation.
Journal ArticleDOI
Adolescent and Caregiver Experiences With Epilepsy
Miya R. Asato,Ranjani Manjunath,Raj D. Sheth,Stephanie J. Phelps,James W. Wheless,Collin A. Hovinga,Jesus E. Pina-Garza,Lisa S. Haskins,Wendy M. Zingaro +8 more
TL;DR: An adolescent-centered epilepsy management program may help alleviate concerns and also help the adolescent independently manage their epilepsy as they transition into adulthood.
Journal ArticleDOI
Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders.
TL;DR: Lamotrigine ODT was found to be significantly more convenient to use than lamotigine immediate-release and both formulations were associated with good satisfaction, and may be a treatment option for patients who have difficulty swallowing medication.
Journal Article
Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
TL;DR: This study assessed the direct economic burden of restless legs syndrome among patients treated with dopamine agonists using a large United States managed care database and found relatively low costs associated with RLS treatment.